According to the IPD Analytics team, an adalimumab biosimilar launch may occur as early as late 2022.

Pharmaceutical expenditure was looked at in this study using IPD Analytics pipeline drug data as a source to predict future potential growth

Ernst and Young announced Howard Krass of IPD Analytics was named an Entrepreneur of the Year® 2020 Florida Award winner.

IPD Analytics experts discussed the impact of Covid-19 on the drug pipeline.

IPD Analytics experts discussed biosimilar competition on MJH Life Sciences News Network

With conversion of the BLA pathway, new launches may receive interchangeability. New insulin products are being launched in the near future

According to interviewed experts at IPD Analytics, the 2020 drug pipeline includes a large number of generic launches.

IPD Analytics discussed both the generic and biosimilar drugs coming to market, and implications for managed care pharmacy at AMCP eLearning

The pace of clinical trials have been affected by COVID-19, according to IPD Analytics' experts on the pharmaceutical pipeline.

There is some difference in opinion regarding how payers will set their formulary management strategy on GLP-1's.

Experts from IPD Analytics discuss payer management of biosimilars in the U.S. market.

In this Q&A from Advisory Board, IPD Analytics' experts discussed what providers need to know about the U.S. biosimilar market.

Pharmaceutical expenditure was looked at in this study using IPD Analytics pipeline drug data as a source to predict future potential growth

IPD Analytics and ICER are collaborating to enhance drug pricing transparency.